Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides

References

• MackenziePCioffiGHow does lowering of intraocular pressure protect the optic nerve?Surv Ophthalmol200853Suppl 1S39S4319038623
   PubMed Web of Science ®Google Scholar
• TianBGabeltBTGeigerBKaufmanPLThe role of the actomyosin system in regulating trabecular fluid outflowExp Eye Res20098871371718793636
   PubMed Web of Science ®Google Scholar
• Lutjen-DrecollEFunctional morphology of the trabecular meshwork in primate eyesProg Retin Eye Res199918911199920500
   PubMed Web of Science ®Google Scholar
• LitonPBLunaCChallaPEpsteinDLGonzalezPGenome-wide expression profile of human trabecular meshwork cultured cells, non-glaucomatous and primary open angle glaucoma tissueMol Vis20061277479016862071
   PubMed Web of Science ®Google Scholar
• Lutjen-DrecollEMorphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the diseaseExp Eye Res2005811415978248
   PubMed Web of Science ®Google Scholar
• OverbyDRStamerWDJohnsonMThe changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endotheliumExp Eye Res20098865667019103197
   PubMed Web of Science ®Google Scholar
• JohnsonDHTrabecular meshwork and uveoscleral outflow modelsJ Glaucoma20051430831015990614
   PubMed Web of Science ®Google Scholar
• WoodwardDFGilDWThe inflow and outflow of anti-glaucoma drugsTrends Pharmacol Sci20042523824115120486
   PubMed Web of Science ®Google Scholar
• SchwartzGFQuigleyHAAdherence and persistence with glaucoma therapySurv Ophthalmol200853Suppl 1S57S6819038625
   PubMed Web of Science ®Google Scholar
• Sharts-HopkoNCGlynn-MilleyCPrimary open-angle glaucomaAm J Nurs20091094047; quiz 48.19299999
   PubMed Web of Science ®Google Scholar
• SchachtschabelULindseyJDWeinrebRNThe mechanism of action of prostaglandins on uveoscleral outflowCurr Opin Ophthalmol20001111211510848216
   PubMedGoogle Scholar
• EasthopeSEPerryCMTopical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertensionDrugs Aging20021923124812027782
   PubMed Web of Science ®Google Scholar
• HodgeWGLachaineJSteffensenIThe efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic reviewBr J Ophthalmol20089271218156371
   PubMed Web of Science ®Google Scholar
• BeanGWCamrasCBCommercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differencesSurv Ophthalmol200853Suppl 1S69S8419038626
   PubMed Web of Science ®Google Scholar
• ChengJWWeiRLMeta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressureClin Ther20083062263218498911
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCALumleyTHendrikseFPrinsMHSchoutenJSA network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressureJ Clin Epidemiol2009621279128319716679
   PubMed Web of Science ®Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• StumpffFWiederholtMRegulation of trabecular meshwork contractilityOphthalmologica2000214335310657743
   PubMed Web of Science ®Google Scholar
• FerrerETrabecular meshwork as a new target for the treatment of glaucomaDrug News Perspect20061915115816804567
   PubMedGoogle Scholar
• WiederholtMThiemeHStumpffFThe regulation of trabecular meshwork and ciliary muscle contractilityProg Retin Eye Res20001927129510749378
   PubMed Web of Science ®Google Scholar
• WiederholtMDirect involvement of trabecular meshwork in the regulation of aqueous humor outflowCurr Opin Ophthalmol19989464910180513
   PubMedGoogle Scholar
• WanZWoodwardDFCornellCLBimatoprost, prostamide activity, and conventional drainageInvest Ophthalmol Vis Sci2007484107411517724194
   PubMed Web of Science ®Google Scholar
• ThiemeHSteinhausenKOttleczAEffects of unoprostone and endothelin 1 on L-type channel currents in human trabecular meshwork cellsOphthalmic Res20053729330016118512
   PubMed Web of Science ®Google Scholar
• OoiYHOhDJRheeDJEffect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cellsInvest Ophthalmol Vis Sci2009505259526519443729
   PubMed Web of Science ®Google Scholar
• WoodwardDFLiangYKraussAHProstamides (prostaglandin-ethanolamides) and their pharmacologyBr J Pharmacol200815341041917721551
   PubMed Web of Science ®Google Scholar
• CantorLBClinical pharmacology of bimatoprostExpert Opin Drug Metab Toxicol2005115115716922657
   PubMedGoogle Scholar
• WanZWoodwardDFStamerWDEndogenous bioactive lipids and the regulation of conventional outflow facilityExpert Rev Ophthalmol2008345747019381354
   PubMedGoogle Scholar
• RussHHCostaVPFerreiraFMConjunctival changes induced by prostaglandin analogues and timolol maleate: a histomorphometric studyArq Bras Oftalmol20077091091618235898
   PubMedGoogle Scholar
• RichterMKraussAHWoodwardDFLutjen-DrecollEMorphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamideInvest Ophthalmol Vis Sci2003444419442614507888
   PubMed Web of Science ®Google Scholar
• HowACKumarRSChenYMA randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucomaBr J Ophthalmol20099378278619336424
   PubMed Web of Science ®Google Scholar
• KurtzSMannOIncidence of hyperemia associated with bimatoprost treatment in naive subjects and in subjects previously treated with latanoprostEur J Ophthalmol20091940040319396785
   PubMed Web of Science ®Google Scholar
• KammerJKatzmanBAckermanSHollanderDEfficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomized, masked-evaluator, multicenter studyBr J Ophthalmol200991 [Epub ahead of print].
   Web of Science ®Google Scholar
• ChenJDinhTWoodwardDFBimatoprost: mechanism of ocular surface hyperemia associated with topical therapyCardiovasc Drug Rev20052323124616252016
   PubMed Web of Science ®Google Scholar
• HenryJCPeaceJHStewartJAStewartWCEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapyClin Ophthalmol2008261362119668762
   PubMedGoogle Scholar
• GuenounJMBaudouinCRatPPaulyAWarnetJMBrignole-BaudouinFIn vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cellsInvest Ophthalmol Vis Sci2005462444245015980234
   PubMed Web of Science ®Google Scholar
• AlmAGriersonIShieldsMBSide effects associated with prostaglandin analog therapySurv Ophthalmol200853Suppl 1S93S10519038628
   PubMed Web of Science ®Google Scholar
• Rodrigues MdeLFelipe CrostaDPSoaresCPImmunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatmentJ Glaucoma20091819720019295371
   PubMed Web of Science ®Google Scholar
• KozakKRCrewsBCMorrowJDMetabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamidesJ Biol Chem2002277448774488512244105
   PubMed Web of Science ®Google Scholar
• WeberANiJLingKHFormation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometryJ Lipid Res20044575776314729864
   PubMed Web of Science ®Google Scholar
• MoriuchiHKodaNOkuda-AshitakaEMolecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamilyJ Biol Chem200828379280118006499
   PubMed Web of Science ®Google Scholar
• PatrignaniPTacconelliSSciulliMGCaponeMLNew insights into COX-2 biology and inhibitionBrain Res Brain Res Rev20054835235915850674
   PubMedGoogle Scholar
• WoodwardDFCarlingRWCornellCLThe pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 productsPharmacol Ther2008120718018700152
   PubMed Web of Science ®Google Scholar
• BurkRMWoodwardDFA historical perspective and recent advances in prostamide research and therapeuticsCurr Opin Drug Discov Devel200710413421
   PubMedGoogle Scholar
• WoodwardDFKraussAHChenJThe pharmacology of bimatoprost (Lumigan)Surv Ophthalmol200145Suppl 4S337S34511434936
   PubMed Web of Science ®Google Scholar
• SmidSDGastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestineClin Exp Pharmacol Physiol200835111383138718671715
   PubMed Web of Science ®Google Scholar
• ChenJLuRTLaiRBimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptorsCurr Eye Res20093418419519274525
   PubMed Web of Science ®Google Scholar
• MatiasIChenJDe PetrocellisLProstaglandin ethanolamides (prostamides): in vitro pharmacology and metabolismJ Pharmacol Exp Ther200430974575714757851
   PubMed Web of Science ®Google Scholar
• WoodwardDFKraussAHWangJWIdentification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline irisBr J Pharmacol200715034235217179945
   PubMed Web of Science ®Google Scholar
• DaviesSSJuWKNeufeldAHAbranDChemtobSRobertsLJ2ndHydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitroJ Ocul Pharmacol Ther200319455412648303
   PubMed Web of Science ®Google Scholar
• RomanoMRLogranoMDEvidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscleInvest Ophthalmol Vis Sci2007483677368217652738
   PubMed Web of Science ®Google Scholar
• SzczesniakAMKellyMEWhynotSShekPNHungOOcular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in ratsJ Ocul Pharmacol Ther20062216016716808676
   PubMed Web of Science ®Google Scholar
• McIntoshBTHudsonBYegorovaSJollimoreCAKellyMEAgonist-dependent cannabinoid receptor signalling in human trabecular meshwork cellsBr J Pharmacol20071521111112017922024
   PubMed Web of Science ®Google Scholar
• LiangYWoodwardDFGuzmanVMIdentification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexesBr J Pharmacol20081541079109318587449
   PubMed Web of Science ®Google Scholar
• WeiYWangXWangLPresence and regulation of cannabinoid receptors in human retinal pigment epithelial cellsMol Vis2009151243125119547718
   PubMed Web of Science ®Google Scholar
• StamerWDGolightlySFHosohataYCannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissuesEur J Pharmacol200143127728611730719
   PubMed Web of Science ®Google Scholar
• CrandallJMatragoonSKhalifaYMNeuroprotective and intraocular pressure-lowering effects of (−)Delta9-tetrahydrocannabinol in a rat model of glaucomaOphthalmic Res200739697517284931
   PubMed Web of Science ®Google Scholar
• NjieYFHeFQiaoZSongZHAqueous humor outflow effects of 2-arachidonylglycerolExp Eye Res20088710611418597752
   PubMed Web of Science ®Google Scholar
• NjieYFQiaoZXiaoZWangWSongZHN-arachidonylethanolamide-induced increase in aqueous humor outflow facilityInvest Ophthalmol Vis Sci2008494528453418539938
   PubMed Web of Science ®Google Scholar
• ChenJMatiasIDinhTFinding of endocannabinoids in human eye tissues: implications for glaucomaBiochem Biophys Res Commun20053301062106715823551
   PubMed Web of Science ®Google Scholar
• MaihofnerCSchlotzer-SchrehardtUGuhringHExpression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyesInvest Ophthalmol Vis Sci2001422616262411581208
   PubMed Web of Science ®Google Scholar
• RoschSRamerRBruneKHinzBR(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cellsJ Pharmacol Exp Ther20063161219122816330497
   PubMed Web of Science ®Google Scholar
• RoschSRamerRBruneKHinzBProstaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinasesBiochem Biophys Res Commun20053381171117816256948
   PubMed Web of Science ®Google Scholar
• NucciCGasperiVTartaglioneRInvolvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in ratsInvest Ophthalmol Vis Sci2007482997300417591864
   PubMed Web of Science ®Google Scholar
• MarshallJLStanfieldKMSilvermanLKhanKNEnhanced expression of cyclooxygenase-2 in glaucomatous dog eyesVet Ophthalmol20047596214738509
   PubMed Web of Science ®Google Scholar
• GlassMHongJSatoTAMitchellMDMisidentification of prostamides as prostaglandinsJ Lipid Res2005461364136815863842
   PubMed Web of Science ®Google Scholar
• HinzBRoschSRamerRTammERBruneKLatanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanismFASEB J2005191929193116076963
   PubMed Web of Science ®Google Scholar
• FraunfelderFWSolomonJMehelasTJOcular adverse effects associated with cyclooxygenase-2 inhibitorsArch Ophthalmol200612427727916476901
   PubMedGoogle Scholar
• RadiZARenderJAThe pathophysiologic role of cyclo-oxygenases in the eyeJ Ocul Pharmacol Ther20082414115118355129
   PubMed Web of Science ®Google Scholar
• CostagliolaCParmeggianiFCaccavaleASebastianiANimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucomaAm J Ophthalmol200614137938116458700
   PubMed Web of Science ®Google Scholar
• NucciCBariMSpanoAPotential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotectionProg Brain Res200817345146418929127
   PubMed Web of Science ®Google Scholar